Somfit D FDA
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Compumedics Limited announced that the U.S. Food and Drug Administration has granted clearance for its Somfit®D device, which is a single-use Home Sleep Testing solution, effectively doubling the addressable U.S. market for the product. The clearance allows Compumedics to tap into a significant annual market for home sleep testing, which has been rapidly shifting towards single-use devices. The company aims to leverage its existing U.S. salesforce and established relationships to commence immediate commercialization of Somfit®D. Compumedics reaffirms its revenue guidance for the upcoming fiscal year, anticipating substantial contributions from the new device as market adoption increases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/somfit-d-fda
Earlier from Compumedics
- Business Update FY26
- Preliminary Final Report
- Business Update Asia - $24m agreements signed
- FY25 Business Update - Record sales orders taken
- Compumedics Achieves World-First Adult and Child Optimized Recordings from a Single MEG System
Later from Compumedics
- Trading Halt
- $2.15 Million Capital Raise for Somfit D
- 5th & New MEG Order
- H1 FY25 Update - Record Sales
- 6th & New MEG Order
Follow Compumedics into a list and get an email when it puts out news.
Follow Compumedics